HARROW INC (HROW)

US4158581094 - Common Stock

16.76  +0.6 (+3.71%)

After market: 16.76 0 (0%)

Fundamental Rating

4

HROW gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. HROW may be in some trouble as it scores bad on both profitability and health. HROW is valued quite expensive, but it does show an excellent growth.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

HROW had negative earnings in the past year.
In the past year HROW had a positive cash flow from operations.
In the past 5 years HROW reported 4 times negative net income.
Of the past 5 years HROW 4 years had a positive operating cash flow.

1.2 Ratios

HROW has a better Return On Assets (-10.60%) than 74.87% of its industry peers.
The Return On Equity of HROW (-51.74%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.6%
ROE -51.74%
ROIC N/A
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of HROW has declined.
With a decent Gross Margin value of 69.77%, HROW is doing good in the industry, outperforming 74.87% of the companies in the same industry.
In the last couple of years the Gross Margin of HROW has grown nicely.
HROW does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.77%
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%

More info and screens

3

2. Health

2.1 Basic Checks

HROW does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HROW has been increased compared to 1 year ago.
Compared to 5 years ago, HROW has more shares outstanding
The debt/assets ratio for HROW has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.54, we must say that HROW is in the distress zone and has some risk of bankruptcy.
HROW's Altman-Z score of 1.54 is fine compared to the rest of the industry. HROW outperforms 64.10% of its industry peers.
A Debt/Equity ratio of 3.04 is on the high side and indicates that HROW has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.04, HROW is doing worse than 83.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.04
Debt/FCF N/A
Altman-Z 1.54
ROIC/WACCN/A
WACC9.58%

2.3 Liquidity

A Current Ratio of 3.00 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Current ratio (3.00) which is comparable to the rest of the industry.
A Quick Ratio of 2.75 indicates that HROW has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.75, HROW is in line with its industry, outperforming 49.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.75

More info and screens

7

3. Growth

3.1 Past

The earnings per share for HROW have decreased strongly by -23.08% in the last year.
HROW shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.81%.
The Revenue has been growing by 25.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-23.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-27.27%
Revenue 1Y (TTM)49.81%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Revenue growth Q2Q32.51%

3.2 Future

Based on estimates for the next years, HROW will show a very strong growth in Earnings Per Share. The EPS will grow by 58.43% on average per year.
The Revenue is expected to grow by 31.23% on average over the next years. This is a very strong growth
EPS Next Y56.81%
EPS Next 2Y72.87%
EPS Next 3Y64.19%
EPS Next 5Y58.43%
Revenue Next Year41.03%
Revenue Next 2Y40.84%
Revenue Next 3Y32.01%
Revenue Next 5Y31.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

HROW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 22.92 indicates a rather expensive valuation of HROW.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 77.95% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of HROW to the average of the S&P500 Index (20.15), we can say HROW is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 22.92

4.2 Price Multiples

74.87% of the companies in the same industry are more expensive than HROW, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 145.59

4.3 Compensation for Growth

HROW's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 64.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.87%
EPS Next 3Y64.19%

More info and screens

0

5. Dividend

5.1 Amount

HROW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARROW INC

NASDAQ:HROW (5/17/2024, 7:04:30 PM)

After market: 16.76 0 (0%)

16.76

+0.6 (+3.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap592.97M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.92
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.6%
ROE -51.74%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 69.77%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3
Quick Ratio 2.75
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-23.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y56.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)49.81%
Revenue growth 3Y38.63%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y